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Abstract: MEIS proteins are historically associated with tumorigenesis, metastasis, and invasion in cancer. MEIS and associated PBXHOX proteins may act as tumor suppressors or oncogenes in different cellular settings. Their expressions tend to be misregulated in
various cancers. Bioinformatic analyses have suggested their upregulation in leukemia/lymphoma, thymoma, pancreas, glioma, and
glioblastoma, and downregulation in cervical, uterine, rectum, and colon cancers. However, every cancer type includes, at least, a
subtype with high MEIS expression. In addition, studies have highlighted that MEIS proteins and associated factors may function as
diagnostic or therapeutic biomarkers for various diseases. Herein, MEIS proteins and associated factors in tumorigenesis are discussed
with recent discoveries in addition to how they could be modulated by noncoding RNAs or newly developed small-molecule MEIS
inhibitors.
Key words: MEIS, cancer, small molecules, MEIS inhibitors

1. Introduction
Homeobox (Hox) genes are transcription factors that are
characterized by a conserved 60-amino acid DNA-binding
domain called homeodomain (HD) (Abate-Shen, 2002).
They are important regulators of cell fate, development,
tumorigenesis, and stem cell function (Abate-Shen, 2002).
They finely regulate organogenesis in nonvertebrates and
are also involved in molecular pathways that determine
vertebrate development (Mallo and Alonso, 2013). The
expression of Hox genes is modulated by nuclear dynamics,
transcriptional regulation, long noncoding RNAs
(lncRNAs), RNA processing, miRNAs, and translational
events (Mallo and Alonso, 2013).
The 3 amino acid loop extension (TALE) proteins are
one of the major HD proteins, that include 27 members
characterized by Meis1-3, Pbx1-4, Irx1-6, Mkx, Pknox1-2,
Tgif1-2, and their pseudogenes (Sitwala et al., 2008; Pillay
et al., 2010). There are 3 Meis isoforms, called Meis1, Meis2,
and Meis3, in mammals (Sonnet et al., 2012). Interestingly,
expression levels of Meis isoforms are quite different from
one another in each cell (Sonnet et al., 2012). The Meis1
gene was first identified in myeloid leukemia using BXH2

mice. It acts as a viral integration site in myeloid leukemia
mice (Moskow et al., 1995).
MEIS1 and PBX regulatory protein-1 (PREP1)
compete functionally with each other (Blasi et al., 2017).
Meis1 overexpression induces tumor formation in Prep1silenced mouse embryonic fibroblasts (Dardaei et al.,
2014). MEIS, HOX, and PBX proteins bind to DNA as a
heterodimer or trimeric structures (Chang et al., 1997).
MEIS-, HOX-, and PBX-generated trimeric structures
increase the half-life of the complex (Shanmugam et
al., 1999). PBX proteins modulate cellular signaling
pathways, including Notch and Smad, and are involved
in chromosomal remodeling (Laurent et al., 2008). When
PBX transcription factors malfunction, organ failure, and
cardiovascular diseases could occur during development
(Laurent et al., 2008). On the other hand, the deletion of
Meis1 downregulates p21, p15, p16, and p19arf expression
in cardiomyocytes and improves the cell cycle (Muralidhar
and Sadek, 2016). Intriguingly, the overexpression of
MEIS proteins may cause caspase-dependent apoptosis in
some cells (Wermuth and Buchberg, 2005). PBX-MEIS1
protein-protein interaction is required for the induction of
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caspase-3- and caspase-8-dependent apoptosis (Wermuth
and Buchberg 2005). MEIS2-PBX heterodimer finely
regulates pancreatic and duodenal homeobox 1 (Pdx1)
expression in the acinar cells of the pancreas (Swift et al.,
1998). Generally, Meis3 expression is involved in neural
development (Uribe and Bronner, 2015). MEIS3 provides
β-cell survival by targeting phosphoinositide-dependent
protein kinase 1 (Liu et al., 2010). However, HOXA9MEIS1 interaction has an inhibitory effect on apoptosis
in Reh human lymphoblastoma cells, HL-60, 32Dcl3, and
NIH3T3 cells (Wermuth and Buchberg, 2005).
Since the expression of Meis isoforms is different in
various cell types and tissues, this suggests that expression
of MEIS proteins may have cell-specific outcomes. Somers
et al. (2016) studied cytotoxicity in different mixed-lineage
leukemia (MLL) cells. They showed that the downregulation
of Meis1, Hoxa9, c-Myc, and Bcl2 were associated with
caspase-dependent apoptosis. The upregulation of MiR155, which is a major inducer of the Meis pathway, leads to
caspase-dependent apoptosis involving c-Jun N-terminal
kinase signaling in acute myeloid leukemia (AML)
(Palma et al., 2014). In addition, transient overexpression
of Meis1 induces caspase-dependent apoptosis in Reh
human lymphoblastoma, Jurkat T, HL-60, and 32Dcl3
cells (Wermuth and Buchberg, 2005). Although the MEISdependent apoptosis response has not yet been fully
elucidated, there is a relationship between MEIS proteins
and apoptosis.
MEIS proteins have been studied in developmental
biology, stem, and progenitor cells in different cell types
and conditions. Using clustered regularly interspaced short
palindromic repeats/Cas9 technology, it was revealed that
Meis1 is a significant regulator for the differentiation of
human pluripotent stem cells (hPSCs) into functional
hematopoietic cells (Wang et al., 2018a). Meis1 is
essential for normal hematopoiesis, as was indicated by
Meis1 mutant mice having an internal hemorrhage, liver
hypoplasia, and anemia (Azcoitia et al., 2005). MEIS1
suppresses the generation of reactive oxygen species (ROS)
and induces scavenging by targeting hypoxia inducible
factors (HIF-1α and HIF-2α) in hematopoietic stem cells
(Kocabas et al., 2012). Thus, MEIS1 protects hematopoietic
stem cells against ROS by maintaining the glycolytic
metabolic phenotype (Kocabas et al., 2012). MEIS-PBX
heterodimers are indispensable in neurogenesis (Azcoitia
et al., 2005). Dopaminergic periglomerular neuron
proliferation in the olfactory bulb is provided by MEIS2
via forming a heterodimer with PAX6 and DLX2 (Agoston
et al., 2014). The MEIS2-PBX1 heterodimer could also
alter the structure of chromatin, and thus modulate the
activity of the genes. The MEIS2-PBX1 heterodimer, for
instance, recruits poly-ADP-ribose (PAR) polymerase 1

(PARP1/ARTD1) in order to regulate PARP1 activity on
the chromosome (Hau et al., 2017).
2. MEIS and associated factors in tumorigenesis
Studies have shown that MEIS proteins and their cofactors
are misregulated in various cancers. These studies have
highlighted that MEIS proteins maybe diagnostic and
therapeutic biomarkers for cancer and other associated
diseases. Thus, herein, the function of MEIS and its
associated factors in solid and nonsolid tumors, as well as
recent therapeutic approaches, including small molecules
and noncoding RNAs in MEIS-related cancers, will be
discussed.
2.1. Bladder cancer
Even though it is known that MEIS partners directly
regulate tumor progression along with HOX proteins,
the definitive role of MEIS proteins remains unclear in
bladder cancer. Hoxa13 and Hoxb13 are, for instance,
known to have high expression in urinary bladder
cancer (Marra et al., 2013; Hu et al., 2017) Hox antisense
intergenic RNA (HOTAIR) has been proposed as a
marker in bladder cancer (Martinez-Fernandez et al.,
2015; Berrondo et al., 2016). HOTAIR downregulates the
level of microRNA-205, thereby disrupting the balance
of H3K4me3 activity in bladder cancer (Sun et al., 2015).
Under normal circumstances, 11 Hox paralogs in locus C
are involved in healthy urogenital development; however,
in the case of bladder cancer, these gene family variants are
upregulated (Cantile et al., 2003).
Genetic and epigenetic modifications have an important
function in carcinoma formation. DNA hypermethylation
is among the most common and characterized epigenetic
modification in human malignancies. The methylation
level is different between low/intermediate and highgrade nonmuscle invasive bladder cancer (HG-NMIBC)
cohorts for Hoxa9 and Isl1 genes, and the methylation
level of the Hoxa9 promoter is significantly reduced in
HG-NMIBC (Kitchen et al., 2015). Moreover, in recurrent
and progressive tumor samples, Isl1 and Hoxa9 are
displayed by a remarkably high level of methylation when
compared to nonrecurrent tumor samples (Kitchen et al.,
2015). Therefore, parallel methylation of Hoxa9/Isl1 in
HG-NMIBC could be used as a predicted value for tumor
recurrence and progression (Kitchen et al., 2015).
Methylation analysis performed with bladder cancer
tissue samples revealed that Meis1 methylation was
similar in all of the samples, regardless of the age of the
patients (Beukers et al., 2013). On the other hand, Meis1
methylation analysis of patient urine samples of painless
hematuria also showed that Meis1 was a significant
predictor for the presence of urothelial cell carcinoma
(Beukers et al., 2013). Therefore, methylation analysis itself
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is not sufficient for predicting Meis1 function in bladder
cancer, and further research is needed.
Alternative splicing has a significant function in the
posttranscriptional regulation of genes, as well as cancer
development or progression. Polypyrimidine tract binding
protein 1, is a protein that has a function bladder cancer
metastasis, and controls Meis2 and pyruvate kinase
alternative splicing via direct binding to specific introns
of these mRNA transcripts, contributing to bladder cancer
development (Xie et al., 2019). Meis2 was also reported as
overexpressed in bladder cancer tissue when compared
with normal adjacent tissue (Xie et al., 2019). Moreover,
Meis2 knockdown significantly inhibits the migration and
invasion capacities of bladder cancer cells (Xie et al., 2019).
Clarifying the potential role of MEIS proteins and
how they are related to HOX proteins in bladder cancer
will be an important step in determining the molecular
mechanism of bladder cancer and developing new
therapeutic approaches.
2.2. Breast cancer
Breast cancer is a hormone-dependent malignant cancer.
However, estrogen receptor products, estrogen α, estrogen
β, and progesterone, are known to also be activated in
breast cancer via estrogen-independent pathways (Dudek
and Picard, 2008). Therefore, a possible relationship
between MEIS and TALE family proteins in breast cancer
needs to be investigated in both estrogen-independent and
-dependent pathways (Dudek and Picard, 2008; Zhang
et al., 2013). In breast cancer, estrogen receptor induces
Meis1 and Forkhead box P3 (Foxp3) upregulation (Zhang
et al., 2013). MEIS1-FOXP3 interaction with a positive
feed-back mechanism could enhance the expression of
cancer-associated genes under the estrogen receptor
pathway (Zhang et al., 2013). The expression of Meis1,
along with transmembrane protein 25 (Tmem25) and
Reps2, has been suggested to be a marker for breast cancer
prognosis (Doolan et al., 2009). High expression of Meis1,
Tmem25, and Reps2 is a determining factor for evaluating
the probability of relapse and survival of breast cancer
(Doolan et al., 2009). Mutations that affect HOX/PBX/
MEIS interactions may also contribute to breast cancer
(Dard et al., 2018). Interestingly, interactions of HOX/
PBX proteins are unstable in the absence of MEIS and
their expressions are aberrant in breast cancer (Dard et al.,
2018). Taken together, these data indicate that MEIS1 and
associated factors may demonstrate an oncogenic function
in breast cancer development and progression.
2.3. Colorectal and gastric cancers
MEIS, HOX, and HIF-MEIS target genes are largely
misregulated in colorectal cancer (Yuan et al., 2017).
Distant metastasis and associated mortality are closely
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related to Meis2 expression in colorectal cancer (Wan et
al., 2019). In vitro and in vivo studies have suggested that
MEIS2 may inhibit migration, invasion, and the epithelial
to mesenchymal transition of colorectal cancer (Wan et al.,
2019). Moreover, high Meis2 expression may reduce the
overall survival period of patients with colorectal cancer
(Wan et al., 2019).
Different HOX proteins have been reported to serve
for tumor formation, metastasis, lymph node metastasis,
and cancer stem cells (CSCs) self-renewal in colorectal
cancer (Kanai et al., 2010). PBX3 protein, which forms
a heterodimer with MEIS proteins, is overexpressed in
colorectal cancers (Han et al., 2014). PBX3 protein, in
particular, contributes to cell proliferation, invasion, and
metastasis in colorectal cancers by modulating mitogenactivated protein kinases (MAPK)/extracellular-signalregulated kinase (ERK) signaling pathways (Han et al.,
2014). The expression pattern of Hoxa9 has been found
to be more characteristic of colonic adenocarcinomas
(Redline et al., 1994). Hoxa9 mRNA and protein expression
were reported as increased in colorectal tumor tissues
when compared with normal tissues and elevated Hoxa9
expression was correlated with lymph node metastasis
(Watanabe et al., 2018). In addition, the knockdown of
Hoxa9 and Hoxa4 in HT29 cells leads to a significant
decrease in cell proliferation, and their overexpression
causes an increase in the self-renewal ability of colorectal
CSCs (Bhatlekar et al., 2018). Moreover, in colorectal
cancer cells, nucleus accumbens-associated protein 1
(Nac1) expression is elevated, which leads to an increase in
drug resistance by upregulating Hoxa9 expression (Ju et al.,
2017). On the other hand, mir133b downregulates Hoxa9
expression and inhibits colorectal tumor cell proliferation
and migration (Wang et al., 2017).
The expression level of Meis1D27, a truncated splicing
variant of Meis1, has been reported to be decreased in
primary colorectal cancer samples (Crist et al., 2011).
This suggests that Meis1D27 could function as a tumor
suppressor in colorectal cancer (Crist et al., 2011).
Moreover, it has been shown that the BRAF V600E
mutation is related to the methylation of Meis1. In
tumors and colon cancer cell lines, this situation has been
associated with a reduction of both the full-length Meis1
and a truncated isoform Meis1D27 transcript expression
(Dihal et al., 2013).
The development and metastasis of the esophageal
squamous cell carcinoma (ESCC) involve varying and
complicated signaling pathways. Rad et al. (2016) showed
that the expression of Meis1 has a reverse association with
lymph node involvement, metastasis, and tumor staging
in ESCC (Rad et al., 2016). Enhancer of zeste homolog
2 (EZH2) leads to Meis1 downregulation during ESCC
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progression (Rad et al., 2016). Moreover, the expression
of Meis1 was found to be inversely correlated with Sox2
expression in ESCC tumor samples (Rad et al., 2016).
The inverse correlation has also been shown between
mastermind-like transcriptional coactivator 1 and Meis1
in ESCC patients (Abbaszadegan and Moghbeli, 2018).
On the other hand, a positive correlation between Musashi
RNA-binding protein 1 and Meis1 was reported during
ESCC progression (Moghbeli et al., 2016).
Meis1 may function as a tumor suppressor during
gastric cancer progression (Song et al., 2017). Its expression
was diminished in gastric cancer tissues or cell lines;
however, when it was overexpressed, the proliferation,
colony formation, and anchorage-independent growth of
gastric cancer cells were repressed (Song et al., 2017). In
addition, the overexpression of Meis1 could lead to G1/S
cell cycle arrest and cell death of gastric cancer cells (Song
et al., 2017).
2.4. Glioblastoma, glioma, and neuroblastoma
Glioblastoma and neuroblastoma both originate from
nervous system cells (de Weille, 2014). Neuroblastoma is
cancer that occurs in the nervous system during embryonic
development, while glioblastoma occurs in the adult brain
(de Weille, 2014). HOX proteins have been highly studied in
tumors of the nervous system. Studies conducted in U-118,
U-138, and normal human astrocyte glioblastoma cell
lines showed that Hoxc8, Hoxc10, Hoxd1, Hoxd4, Hoxd9,
Hoxd10, and Hoxd13 were expressed in glioblastoma
cells, while they were not detected in healthy tissue (Guo
et al., 2016). Hoxc6 and Hoxc10 overexpression regulates
glioblastoma cell proliferation and migration via MAPK
and PI3K/protein kinase B (AKT) signaling pathways,
respectively (Guan et al., 2019; Yang et al., 2019). HOXA13
promotes cancer invasion by wingless/integration (Wnt)
and transforming growth factor (TGF)-β pathways (Duan
et al., 2015). Intriguingly, HOXA10 allows glioblastoma
cells to develop resistance to chemotherapy agents (Kim
et al., 2014).
The Pbx3 mRNA and protein content is higher
in glioblastoma cells. The migration and invasion of
glioblastoma cells is triggered by PBX3/MEK/ERK1/2/
LIN28/let-7b (Xu et al., 2018). In vivo Pbx3 suppression
resulted in a reduced invasion of glioblastoma (Xu et al.,
2018). However, there is still a need to establish the direct
role of MEIS proteins in glioblastoma. Given the high
level of Meis1-2-3 expression in glioblastoma tissues, a
study examining the relationship between MEIS1-2-3 and
glioblastoma is clearly needed.
Glioma, one of the most prevalent and heterogeneous
tumors of the brain, is characterized by high morbidity and
death rates (Weller et al., 2015). These tumors are thought
to originate from the neuroglial stem or progenitor cells
(Weller et al., 2015; Chen et al., 2017). Nuclear receptor

SET domain-containing protein-1 (NSD1) silencing by
epigenetic modification leads to Sotos syndrome, as well
as nonhereditary neuroblastoma and glioma development
(Berdasco et al., 2009). Hypermethylation of Nsd1 causes
the upregulation of Meis1 transcript and protein due to
the absence of NSD1 binding to the Meis1 promoter in
neuroblastoma cells (Berdasco et al., 2009). A high level of
Meis1 transcript has also been seen in the lymphoblastoid
cells of patients with Sotos syndrome as a result of NSD1
silencing (Berdasco et al., 2009). Gene expression analysis
of glioma and glioblastoma cells revealed that Meis2 was
one of the differentially expressed genes and it could be
a prognostic biomarker for glioma and glioblastoma
development, in addition to with other genes, including
Meox2, Pitx2, Nr2e1, and Tfap2B (Vastrad et al., 2017).
miR-638 modulates Hoxa9 expression in glioma cell lines
(Zheng et al., 2018). It has been shown that miR-638
expression is related to tumor size and score in glioma.
The overexpression of Hoxa9 clears the tumor suppressor
effects of miR-638 (Zheng et al., 2018). Moreover, cyclin
D1 and c-Myc are controlled by miR-638 and Hoxa9
(Zheng et al., 2018).
The gene expression analysis of spinal cord
ependymomas revealed that 105 genes were upregulated
(Kim et al., 2018). Among them, Arx, Hoxc6, Hoxa9,
Hoxa5, and Hoxa3 were the 5 top-ranked genes (Kim et
al., 2018). Another gene expression analysis revealed that
HOTAIR was overexpressed in high-grade gliomas and it
was likely controlled by DNA methylation along with the
coexpression of Hoxa9 (Xavier-Magalhaes et al., 2018).
Therefore, these 2 genes could be a prognostic marker for
high-grade gliomas. Immunohistochemical analysis in
patients with clinical intramedullary spinal tumors showed
that both Hoxa9 and Hoxb13 had been upregulated (Gu
et al., 2017). Moreover, they were found to be involved
in spinal ependymoma and myxopapillary ependymoma
development, respectively (Gu et al., 2017). Taken together,
each member of the HOX family of proteins has unique
functions in glioma; thus, they could be useful as specific
markers of the disease.
Analysis of Hox genes in neuroblastoma began in
the early 1990s (Peverali et al., 1990). Neuroblastoma
differentiation using retinoic acid was found to result
in Hox gene upregulation (Manohar et al., 1993). The
expression levels of Hoxc6, Hoxd1, and Hoxd8 genes
were increased significantly by chemical induction,
while the expression of Hox genes was undetectable
in undifferentiated neuroblastomas. In addition, the
expression of Hoxd4 and Hoxd9 were detected at low levels
in human neuroblastoma cells (Manohar et al., 1996).
Hoxc9 may act as a tumor suppressor and upregulated
Hoxc9 may activate the intrinsic apoptosis signaling
pathways in neuroblastoma cells (Kocak et al., 2013).
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The TALE homeobox genes are very important for
the standard development of the nervous system. They
have been implicated in neuroblastoma, glioma, and
glioblastoma. Most TALE subfamilies (including Meis1,
Meis2, and Pbx2) are upregulated in a set of neuroblastoma
cell lines, suggesting that the regulation of TALE
transcription is functional in tumorigenesis (Jones et al.,
2000; Spieker et al., 2001; Geerts et al., 2003; Berdasco et
al., 2009). Intriguingly, stable transfection of the dominantnegative variant of MEIS1 has generated clones with altered
cell proliferation, increased differentiated phenotype,
and elevated contact inhibition and cell death. Similarly,
MEIS2 has been shown to be essential for neuroblastoma
cell survival and proliferation (Zha et al., 2014). In short,
MEIS proteins may act as oncogenes in neuroblastoma, as
reported by Geerts et al. (2003).
PHNOX2B transcription factor is expressed under the
control of MEIS1-PBX1, AP-1, and NF-κB complexes and
has been shown to be one of the major triggering factors of
neuroblastoma (Di Zanni et al., 2015). It was first shown
in 2001 that Meis1 was amplified and overexpressed in
neuroblastoma cancer cells (Spieker et al., 2001). Spieker
et al. (2001) showed, in a serial analysis of gene expression,
that MEIS1 proteins were overexpressed in 22 out of 24
examined neuroblastoma cell lines (Spieker et al., 2001).
The overexpression of Meis1 and Meis2 in neuroblastoma
cells is associated with increased tumor progression (Geerts
et al., 2003). The impairment of cellular proliferation,
differentiated phenotype, and induced cellular death occur
in the case of dominant-negative splice variants of Meis1
expression in neuroblastoma cells (Geerts et al., 2003).
The inhibition of Meis1 and Meis2 expression also causes
apoptosis in neuroblastoma cells (Geerts et al., 2003).
Hence, an increased expression of Meis1 and Meis2 may
be involved in the promotion of neuroblastoma formation;
thus, they may act as oncogenes (Geerts et al., 2003).
2.5. Kidney cancer
MEIS1 suppresses cellular differentiation and induces
self-renewal in embryonic kidney malignancies (Dekel
et al., 2006). MEIS1 has a pivotal function in fetal liver
formation, and it is rapidly downregulated during in vitro
differentiation of the kidney (Dekel et al., 2006). Studies have
shown that miRNA-204 expression in nephroblastomas is
reversely correlated with Meis1 expression (Koller et al.,
2014). While miRNA-204 is downregulated, Meis1 and
its binding partner, Pbx2, are upregulated (Koller et al.,
2014). In kidney cancer, HOX proteins are also aberrantly
expressed (Shears et al., 2008). When the interaction
between HOX proteins (such as HOXA3, HOXA4,
HOXA5, HOXA6, HOXA9, HOXB4, HOXB5, HOXB7,
HOXC4, HOXC9, HOXD8, HOXD9, and HOXD10) and
PBX proteins are disrupted, necrosis and apoptosis may
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occur in renal cancer cell lines, such as CaKi-2 and 769-P
(Shears et al., 2008). Studies have suggested that MEIS1
may function as a tumor suppressor in the progression
of clear cell renal cell carcinoma (ccRCC), since the
endogenous expression of Meis1 is reduced in ccRCC
cell lines (Zhu et al., 2017). Furthermore, the elevation of
MEIS1 expression significantly blocks the proliferation
and apoptosis of ccRCC cells (Zhu et al., 2017).
2.6. Leukemia/lymphoma
Leukemia is a disorder in which the red blood cells and
platelets are disabled by an aberrant increase of white
blood cells (Mudgapalli et al., 2019). Meis1 has been
identified as one of the primary factors in the formation
of leukemia (Lasa et al., 2004). Mutations in the MEISHOX signaling pathway and its downstream proteins
have been found to cause MLL (Zhou et al., 2014). PU.1
transcription factor cross-talks with the MEIS-HOX
signaling pathway in leukemia cells, promotes cell cycle
progression, and inhibits cell death (Zhou et al., 2014). In
vivo studies have shown that PU.1 mutation contributes
to MLL development by modulating MEIS-HOX
downstream genes (Zhou et al., 2014). MEIS1-PBX and
HOX-PBX heterodimer complexes have been shown to
occupy promoter regions of leukemia-related genes (Wang
et al., 2006). The MLL1- WD repeat-containing protein 5
(WDR5) protein complex allows high expression of Meis1
and Hox by methylation activity on DNA (Karatas et al.,
2013). It was also found that Hox and Meis1 expression
levels could be decreased via the inhibition of MLL1WDR5 protein-protein interaction (Karatas et al., 2013;
Kempinska et al., 2018). The endogenous expression level
of Meis1 determines the severity of MLL (Wong et al.,
2007). In cases with an inactivation mutation of Meis1 in
fetal liver cells, myeloid transformation loses its capability
for the differentiation and self-renewal of leukemia stem
cells (Wong et al., 2007).
The effects and molecular mechanisms of MEIS
proteins in leukemia have been well-studied (Lasa et
al., 2004). In myeloid cells, MEIS1 is found in a trimeric
form with PBX2 and HOXA9 (Shen et al., 1999). The
trimeric complex occupies the region in which PBX2MEIS1 DNA is bound (Shen et al., 1999). In addition, a
regulatory feedback loop linked to Meis1, along with PU.1,
Syk, and miR-146a, was reported (Mohr et al., 2017).
Myeloid progenitor transformation with Meis1 and Hoxa9
is dependent on SYK-induced Meis1 expression (Mohr
et al., 2017). PBX-MEIS1 heterodimer causes HOXA9mediated immortality of myeloid progenitors (Schnabel et
al., 2000). Intriguingly, MEIS1-PBX2 interaction provokes
chemotherapy resistance towards leukemia (Schnabel et
al., 2000). Cellular differentiation was induced by MEIS1
and other polycomb group proteins in AML patients
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(Grubach et al., 2008). The impairment of MEIS1HOXA4/9 interaction disrupts epigenetic regulation in the
chromosome; therefore, AML formation occurs (Grubach
et al., 2008).
In pediatric pre-B cell acute lymphoblastic leukemia
(pre-B-cell ALL) patients, the Meis1 promoter methylation
level was observed as different from that of the control
group (Musialik et al., 2015). Levels of Meis1 expression
have also been correlated with white blood count
(Musialik et al., 2015). Moreover, pre-B-cell ALL patients
were observed to have E2A-PBX1 chimeric oncoprotein
resulting from chromosomal translocation t(1;19), and
translocation results in mutant oncoprotein (Carroll et al.,
1984). E2A-PBX translocation causes inappropriate tissuespecific gene expression in pre-B cell ALL (Carroll et al.,
1984; Calvo et al., 1999).
MEIS1 and MEIS2 interact with HOX and PBX
variants in leukemia (Garcia-Cuellar et al., 2015). The
presence of PBX3 and MEIS1 increases HOXA9-induced
leukemia (Garcia-Cuellar et al., 2015). PBX3 enhances the
stability of MEIS1 and PBX3-MEIS1 heterodimer triggers
the further transcription of Meis1 (Garcia-Cuellar et al.,
2015). The trimeric structure of HOXA9/MEIS1/PBX3
supports HOXA9-driven leukemia (Garcia-Cuellar et
al., 2015). In addition, Meis2 is overexpressed in myeloid
leukemia mice, resulting in the conclusion that MEIS1 and
MEIS2 may have a parallel function in myeloid leukemia
(Rieckhof et al., 1997; Fujino et al., 2001).

MEIS1 has been found to be a very important
regulator for the differentiation of hPSCs into functional
hematopoietic cells (Wang et al., 2018b). MEIS1 controls
hematopoietic differentiation via targeting T-cell acute
lymphocytic leukemia 1 (TAL1) and Friend leukemia
integration 1 (FLI1) transcription factors (Wang et
al., 2018a). MEIS2 regulates early hematopoietic
differentiation in human embryonic stem cells (Wang et
al., 2018a). The deletion of Meis2 differentially modulates
TAL1, and thereby impairs endothelial specification and
endothelial to hematopoietic transition (Wang et al.,
2018b).
Aberrant expression of Tlx1/Hox11 also results in
T-cell leukemogenesis via Meis1 and Meis2 (Milech et
al., 2010). Meis1 or Meis2 and Tlx1 are coexpressed and
interact with each other (Milech et al., 2010). Intriguingly,
Tlx1 expression has not been observed in B-lineage ALL
or primary lymphocytes (Milech et al., 2010). It has been
found that Meis1/Hoxa9 deregulation has an important
function in the progression of leukemia (Collins and Hess,
2016). Meis1 mutations lead blood cells to develop the
symptoms of leukemia, as well as gain the chemoresistance
and proliferation of leukemia cells by triggering other
MEIS-cofactors (summarized in Table 1).
2.7. Lung cancer
The ectopic expression of Meis1 has been shown to inhibit
cell proliferation in nonsmall-cell lung cancer (NSCLC)
(Li et al., 2014). This was in parallel with the finding that

Table 1. MEIS proteins and associated factors involved in leukemia/lymphoma.
Associated factor/event

Component complex

Associated disorder

Reference

PU1

MEIS1 and PBX3

MLL

Zhou et al. (2014)

HOXA9

MEIS1 and PBX3

Leukemogenesis

Wang et al. (2006)

AML1-ETO

MEIS1

AML

Lasa et al. (2004)

FLT3

MEIS1 and HoxA9

AML

Staffas et al. (2017)

E2A-PBX1

MEIS1 and PREP1

Myeloid immortalization

Calvo et al. (1999)

Polycomb group genes (PcG)

MEIS1, HOXA4, and HOXA9

AML

Grubach et al. (2008)

SYK, PU1, and miR-146a

MEIS1 and HOXA9

AML

Mohr et al. (2017)

TLX1/HOX11

MEIS1 and MEIS2

T-cell ALL

Milech et al. (2010)

Translocation

t(10;14)(q24;q11)- HOX11(TCL3) T-cell leukemia

Misregulated Hox genes

MEIS1, PBX2, and PBX3

Zutter et al. (1990)

Leukemia stem cells of MLL Sitwala et al. (2008)

Aberrant MEIS1 promoter methylation Meis1

Pediatric B-cell ALL

Musialik et al. (2015)

Impaired (MLL1)-WDR5 interaction

MEIS1 and HOXA9

MLL

Karatas et al. (2013)

HOXA9 and Meis1 downregulation

Hoxa9 and Hoxb8

Myeloid differentiation

Fujino et al. (2001)

t(4;11)(q21;q23) translocation

MLL-AF4 fusion gene and
increasing Hoxa9-MEIS1

ALL

Thomas et al. (2005)

MML: mixed-lineage leukemia, ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia.
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the reduction of Meis1 expression led to the proliferation
of NSCLC cells and cell cycle progression (Li et al., 2014).
On the other hand, MEIS1, HOXA5, and T-box 5 proteins
are considered as pathogenicity markers in lung cancer
adenocarcinoma (Du and Zhang, 2015). Thus, PBX2
protein, one of the heterodimer partners of MEIS1, has
been shown to cause cell proliferation, metastasis, and
invasion by activating TGF-β, TGF-β-SMAD3, and sonic
hedgehog signaling pathways (Plowright et al., 2009;
Qiu et al., 2009; Risolino et al., 2014; Pan et al., 2016;
Shi et al., 2017). HOXA5 and p53 work together to play
a role in suppressing lung cancer cell invasion (Chang
et al., 2017). HOXA5 and p53 reduce the level of matrix
metalloproteinase-2 (MMP2), thus inhibiting cell invasion
(Chang et al., 2017). Various HOX proteins (i.e. HOXA1,
HOXA5, HOXA5, and HOXA8) have significant roles in
lung carcinogenesis (Xiao et al., 2014; Chang et al., 2017;
Liu et al., 2018; Zhang et al., 2018). Cell proliferation,
metastasis, cellular survival, and chemoresistance are also
involved in the utilization of the Wnt/β-catenin signaling
pathway in small and NSCLC (Xiao et al., 2014; Chang et
al., 2017; Liu et al., 2018; Zhang et al., 2018). Furthermore,
the differentiation of methylated CpG of Hoxa7 and Hoxa9
genes when compared to healthy controls is a point that
needs to be examined on a molecular level (Rauch et al.,
2007).
HIF proteins are involved in protecting cells against
the action of ROS-dependent apoptosis (Vukovic et al.,
2015). In lung cancer, the effect of HIFs has been the
subject of studies because of the cancer microenvironment
(Vukovic et al., 2015). HIFs are subjected to transcriptional
activation via MEIS1 protein (Vukovic et al., 2015).
NSCLCs have abnormal and elevated HIF-1α expression
(Yang et al., 2017). Blocking of HIF-1α complexes has been
shown to cause increased metastasis and angiogenesis and
an increase in cancer cell proliferation (Lin et al., 2017;
Yang et al., 2017). The consumption of fluorodeoxyglucose
(FDG) in lung cancer cells demonstrates the relationship
between HIF-1α and HIF-2α (Higashi et al., 2016).
Surprisingly, however, cells that have a high expression
of HIF-2α are more aggressive against radiotherapy and
FDG uptake (Sun et al., 2015; Higashi et al., 2016). MEIS1
decreases cell proliferation in small-cell lung cancer (Li
et al., 2014). In summary, MEIS and HOX proteins may
function as a tumor suppressor in lung cancers. However,
further studies including tissue samples of patients are
needed to validate these data.
2.8. Skin cancer
In melanoma cells (namely the MJT1 cell line), MEIS1 and
PBX proteins enhance the stability of the HOX-PBX-DNA
trimeric complex (Aulisa et al., 2009). Disruption of this
trimeric complex by designed peptide amphiphiles has been
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shown to slow down the growth of melanoma cells (Aulisa
et al., 2009). In addition, the 2-stage skin carcinogenesis
mouse model has shown that Meis1 has a protumorigenic
(oncogenic) function in the development of tumor and
malign transformation (Okumura et al., 2014). In the
metastatic melanoma cell line, both mRNA and protein
expression analysis has shown that Pbx2 expression was
elevated when compared to Pbx1, Pbx3, and Pbx4 (Errico
et al., 2013). PBX2 and HOXB7 form a heterodimer
structure and induce miR-221 and miR-222 expression
(Errico et al., 2013). PBX2/HOXB7 heterodimer, along
with miR-221 and miR-222, inhibits c-Fos expression and
apoptosis (Errico et al., 2013). Hoxb7, which is abnormally
expressed in different melanoma cell lines, has been shown
to cause aberrant cell proliferation through the induction
of basic fibroblast growth factor (bFGF) (Carè et al., 1996).
Moreover, it has been shown that miRNA-196a modulates
the expression of target genes (cadherin-11, calponin-1,
and osteopontin) by regulating Hoxc8 in melanocyte and
melanoma cells (Mueller and Bosserhoff, 2011).
Pbx1 is downregulated by promyelocytic leukemia
zinc-finger (PLZF) protein in melanoma cells (Shiraishi et
al., 2007). Furthermore, the knockdown of Pbx1 by short
interfering RNAs (siRNA) leads to the suppression of cell
growth (Shiraishi et al., 2007). Moreover, PBX1 interacts
with HOXB7 in melanoma cells and the downregulation
of Pbx1 causes Hoxb7 and target gene downregulation,
including bFGF, Ang-2, and Mmp9 (Shiraishi et al., 2007).
miR-495 acts as a tumor suppressor by directly targeting
and downregulating Pbx3 (Chen and Xie 2018). Briefly,
miR-495 downregulates proliferation, invasion, and colony
formation, and induces apoptosis in melanoma tissues and
cell lines (Chen and Xie, 2018).
Promoter methylation analysis of primary cutaneous
melanoma has shown that Hoxa9 was hypermethylated in
the samples (Gao et al., 2013). Moreover, a detailed DNA
methylation analysis of all stages of human melanoma
revealed that Hoxa9 DNA hypermethylation had a
function in tumor development when compared to benign
samples (Wouters et al., 2017).
Taken together, Meis1 and Pbx2 may be considered
to have oncogenic properties in skin tumorigenesis. They
contribute to the stability of the HOX-PBX-MEIS tertiary
structure in DNA; thus, they trigger the proliferation of
melanoma cells.
2.9. Oral cancer
Studies have suggested that HOX-PBX interaction allows
the survival of oral malignant and squamous carcinoma
cells (Platais et al., 2018). Following the disruption of
HOX-PBX interaction with double active peptide, c-Fos
expression increases and apoptosis takes place (Platais
et al., 2018). PBX1 and hematopoietic PBX interacting
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proteins (HPIP) cause cell differentiation, proliferation,
metastasis, and invasion in oral cancer (Okada et al., 2015).
The misregulated expression of Hoxc6 and Hoxa10 cluster
proteins are involved in the proliferation, survival and
migration of oral cell carcinoma. Disruption of Hoxc6 and
Hoxa10 gene expression could enhance tumor progression
(Carrera et al., 2015; Tang et al., 2019).
One of the most prevalent cancers of the oral cavity
is SCC. Expression pattern evaluation of Pbx2 (both
mRNA and protein) in patients with gingival SCC (GSCC)
revealed that Pbx2 was upregulated and could be a useful
prognostic marker in these patients (Qiu et al., 2012). The
overexpression of Pbx2 is associated with tumor size, stage,
and metastasis, as well as a high expression of the valosincontaining protein (VCP) in GSCC cells (Qiu et al., 2012).
The hypermethylation of Meis1 has been identified in
adenoid cystic carcinoma samples using the methylated
CpG island amplification and microarray methods, but
further validation studies are needed (Bell et al., 2011). On
the other hand, an analysis of the global methylation status
of 24 Hox genes in oral SCC (OSCC) cell lines revealed
that 12 genes, including Hoxa9, were hypermethylated
(Xavier et al., 2014). Hoxa9 hypermethylation was also
reported in the promoter methylation analysis of OSCC
patient tissues (Guerrero-Preston et al., 2011) and salivary
rinses (Schussel et al., 2013), which leads to the growth
advantage of the tumor, and an increase in metastasis
(Uchida et al., 2014). Contrary to these findings, it was
also reported that Hoxa9 was overexpressed in OSCC
tissue samples (Wang et al., 2017a). Moreover, miR-1395p inhibits cell proliferation, invasion, and migration by
directly targeting Hoxa9 expression (Wang et al., 2017b).
These findings indicate that further investigation is needed
with large patient cohorts to make a clear statement about
the function of Hoxa9 in OSCC development. Pbx2 and
hypermethylation of Meis1 and HoxA9, however, may be
considered prognostic markers of oral cancer.
2.10. Gynecologic cancers
Gynecologic cancer arises from any part of the reproductive
organs of a woman. They have been categorized into
6 main types, comprising ovarian, cervical, uterine
(endometrial-uterine sarcoma), vulvar, vaginal, and
fallopian tube cancers (Stewart et al., 2013). Each of these
types of gynecologic cancers has its own unique risk
factors, development, and treatment strategies (Stewart et
al., 2013). Uterine and ovarian cancers are among the most
common gynecologic cancers (Stewart et al., 2013).
Ovarian cancer studies have shown that Meis1, Meis2,
nuclear, and total cytoplasmic Pbx1–4 RNA expressions,
and protein contents are higher than normal tissue in
both nuclear and cytoplasmic locations (Crijns et al.,
2007). Moreover, MEIS1 has been shown to play a key
role in the early stages of ovarian cancer through its

involvement and regulation of T-cell chemo-attraction
(Karapetsas et al., 2018). Studies about MEIS-PBX
proteins and their correlation with HPIP have suggested
their potential to become key uterine cancer biomarkers.
High Hpip expression correlates with the histological
grade, lymph node metastasis, and relapse of cancer. It
also reduces overall survival in uterine cancer (Yang et al.,
2016). Similarly, lncRNA HOTAIR transcribed from the
Hoxc locus of DNA in uterine cancers leads to cellular
proliferation, metastasis, and radiotherapy resistance via
the MAPK signaling pathway (Li et al., 2018). In addition,
HOTAIR adversely affects tumor relapse and overall
survival time (Li et al., 2015a; Li et al., 2015b).
An analysis of Pbx1 expression in ovarian tumor samples
indicated that Pbx1 was upregulated in these samples,
and the overexpression of Pbx1 led to platinum-based
chemotherapy resistance in patients with ovarian cancer
(Jung et al., 2016). In addition, Meox1 was overexpressed
in ovarian cancer cells along with Pbx1, and the silencing
effects of Pbx1 were reversed by Meox1 expression in the
cell lines (Thiaville et al., 2012). It was also reported that
notch receptor 3 (NOTCH3) is a transcriptional activator
of Pbx1 in ovarian cancer (Park et al., 2008).
The overexpression of NOTCH3 is correlated with the
overexpression of Jagged-1 and Pbx1b in cervical SCCs,
yet there is no established relationship between Pbx1b
overexpression and patient survival (Yeasmin et al., 2010).
PBX3 is overexpressed in the cytoplasm of cervical cancer
cells and tissues and its expression is related to poor
prognosis, tumor diameter, pathological grade, clinical
stage lymph node metastasis, invasion depth, and vascular
invasion (Li et al., 2017). The function of PBX3 is likely
controlled by the AKT signaling pathway in cervical
cancer (Li et al., 2017). The miR-526b miRNA was reduced
in various cancers, including cervical cancer and miR526b expression leads to a decrease in Pbx3 expression in
cervical cancer cells when compared to healthy cells (Li
et al., 2019a). Moreover, the PBX3-mediated epithelial-tomesenchymal transition (EMT) process is associated with
invasion and metastasis that is inhibited by miR-526b in
cervical cancer cells (Li et al., 2019a).
Gene expression analysis revealed that Pbx1–2 and
Hoxb1 regulate Col5a2 expression, which possibly has a
function in the focal adhesion pathway in endometrial
cancer (Zhu et al., 2012). The benign and rare smooth
muscle tumor called retroperitoneal leiomyoma is mostly
found only in women and carries histopathological
features that are very similar to uterine leiomyomas
(Panagopoulos et al., 2015). In a case with retroperitoneal
leiomyoma, it was reported that tumor cells had a t(9;22)
(q33;q12) translocation, which resulted in a fusion of
Ewsr1 and Pbx3 genes (Panagopoulos et al., 2015). Tumorspecific methylation analysis of HoxA9 in patients with
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ovarian cancer in phase II clinical trials with bevacizumab
and tocotrienol chemotherapy revealed that HoxA9
methylation was increased after 1 cycle of chemotherapy
(Thomsen et al., 2019). This suggested that Hoxa9 could
be a possible biomarker for early response to inefficient
chemotherapy in ovarian cancer patients (Thomsen et al.,
2019).
miR-196b, whose expression is upregulated in recurrent
epithelial ovarian cancer (EOC), leads to invasion of
the ovarian cancer cells (Chong et al., 2017). Hoxa9 is
downregulated by the binding of miR-196b to 3′-UTR;
therefore, it could be a possible candidate for antimiR196b
effect (Chong et al., 2017). The aberrantly expressed
Hoxa9 in patients with epithelial ovarian cancer has no
significant predictive value during first-line platinumtaxane chemotherapy (Pontikakis et al., 2017). On the
other hand, a series of studies on ovarian cancer cells
indicated that adaptation to the peritoneal environment
and guidance of different types of stromal cells to reinforce
tumor growth were stimulated by Hoxa9 (Ko and Naora,
2014). Although, the methylation analyses of Hoxa9 with
large cohorts has shown that Hoxa9 is hypermethylated
in both high-grade serous ovarian cancer (Montavon et
al., 2012) and primary ovarian cancer patients, (Wu et
al., 2007) the association of hypermethylation with the
stage, histological types, grade, and ascites could not be
established (Xing et al., 2015). Interestingly, a study on
ovarian cancer cell line and normal tissue showed that
DNA methylation of some of the analyzed genes, including
Hoxa9, Hoxa10, MiR-34b, Prom1, Cables1, Sparc, and
Rsk4, had an inverse correlation with their expression
level (Niskakoski et al., 2014). It has been stated that Rsk4,
Sparc, and Hoxa9 function as oncogenes in ovarian cancer
development, since they have less promotor methylation
correlated with a high-grade tumor (Niskakoski et al.,
2014). The high expression of Hoxa9 in EOC patients
induces P-cadherin via Cdh3 gene activation, which in
turn leads to intraperitoneal dissemination of EOC (Ko and
Naora 2014). The overexpression of HOXA9 is associated
with poor outcomes in EOC patients and Hoxa9 regulates
the activation of cancer-associated fibroblasts by TGF-β2
in EOC cells (Ko et al., 2012).
The expression of Hoxa9 is required for normal cervical
physiology (Lopez et al., 2006) and some cervical cancer
cells have shown a downregulation of Hoxa9 expression,
which is modulated by both methylation and HPV
infection (Alvarado-Ruiz et al., 2016). Moreover, targeting
the human oncogene B-cell-specific moloney murine
leukemia virus integration site 1 in the cervical cancer
cell line leads to Hoxa9 activation (Chen et al., 2011). On
the other hand, another study showed that Hoxa9 was
expressed in both cervical carcinoma cell lines and normal
cervical tissues (Hung et al., 2003).
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Global methylation analysis of Hoxa9 expression in
endometrial cancer tissues and healthy tissues revealed
that Hoxa9 was hypermethylated in cancer tissues (Chen
et al., 2015) and it was associated with lymphovascular
tumor invasion (Makabe et al., 2019). Moreover,
hypermethylation of Hoxa9 was also shown in DNA
samples isolated from the vaginal tampon of endometrial
cancer patients (Bakkum-Gamez et al., 2015).
In summary, studies have suggested that MEIS and
PBX proteins may function as oncogenes in gynecologic
cancers. Interactions between MEIS1 and PBX1–3 are
involved in the early stages of ovarian cancer. In addition,
they are highly expressed in gynecologic cancers when
compared to healthy tissue. However, when all of the
results are evaluated, the oncogenic or tumor-suppressive
role of Hoxa9 in gynecologic cancers is inconclusive.
2.11. Pancreatic cancer
MEIS proteins and their partner PBX1 have been
shown to cooccupy a promoter of keratin 19 during
pancreas development (Deramaudt et al., 2006). T3M4,
a cellosaurus cell line, is known to have stimulated
cell proliferation through the formation of HOXB2A10-PBX HD heterodimers and associated pancreatic
carcinogenesis (Aulisa et al., 2009). When HOXB2-A10PBX HD complex and target DNA interaction is impaired
with a specifically designed peptide, cell proliferation
significantly decreases (Aulisa et al., 2009). MEIS1 is
an important transcription factor that regulates the
expression of mitochondrial genes (Tomoeda et al., 2011).
MEIS1 protein may alter mitochondrial activity and it is
associated with metabolic pathways in pancreatic cancer
(PaC) (Tomoeda et al., 2011). Studies have shown that the
expression of mitochondrial genes could be downregulated
when Meis1 specific siRNA was transfected into PaC cells
(Tomoeda et al., 2011). In addition, MEIS proteins could
contribute to the Warburg effect to facilitate the abnormal
growth of cells in the hypoxic tumor microenvironment
via transactivation of HIFs and cooperation with HOX
proteins. HOX proteins are also known to help the survival
of cancer cells by activating ERK1/2 signaling pathways and
modulating epigenetic pathways in cancer cells (Tsuboi et
al., 2017). Meis1 is overexpressed in primary pancreatic
ductal adenocarcinoma cells and results in activation
of the melanoma cell adhesion molecule that causes cell
migration (von Burstin et al., 2017). On the other hand,
global gene expression analysis of nonmetastatic pancreatic
endocrine neoplasms and metastatic pancreatic endocrine
neoplasms revealed that Meis2 was downregulated in
metastatic pancreatic endocrine neoplasms (Hansel et al.,
2004).
Pbx1 was differentially expressed in inflammationassociated pancreatic stellate cells (PaSCs) when
compared to tumor-associated PaSCs (Scarlett et al.,
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2011). Mesothelin is upregulated in most PaCs and causes
miR-198 downregulation via NF-κB-mediated OCT-2
induction (Marin-Muller et al., 2013). In addition, the
inhibition of miR-198 leads to the upregulation of Pbx1 and VCP, which causes tumor progression (MarinMuller et al., 2013). In PaC cells, overexpression of Pbx3
is associated with tumor development and miR-129-5p
prevents the proliferation and migration of cancer cells by
targeting Pbx3 (Qiu et al., 2019).
The lncRNA HOXA transcript at the distal tip
(HOTTIP) is upregulated in pancreatic CSCs (PCSCs)
and pancreatic cell lines (Fu et al., 2017). HOTTIP is an
important factor for the maintenance of PCSCs (Fu et al.,
2017). Binding of the HOTTIP to WDR5 induces Hoxa9
expression, which is also a significant factor for PCSCs
maintenance (Cheng et al., 2015; Fu et al., 2017). The mir210, a hypoxia-inducible miRNA, inhibits tumor growth
of PaC by targeting Hoxa1, Fgfrl1, and Hoxa9 (Huang et
al., 2009).
In summary, MEIS, PBX, and HOX proteins may
function as oncogenes in PCs. MEIS1 and PBX3 provide
metastatic capabilities to pancreatic tumors. PBX1
is involved in tumor progression. However, MEIS2
demonstrates low expression in metastatic PaCs (Hansel
et al., 2004).
2.12. Prostate cancer
Mutations in Hoxb13 generate a critical risk of developing
prostate cancer (PC) (Johng et al., 2019). HOXB13, which
enables the coactivation of the androgen receptor (AR)
and Foxa1, forms a heterodimer with MEIS1 (Johng et
al., 2019). Expression levels of butyrylcholinesterase and
TNF superfamily member 10 were decreased in PC cells
by MEIS1 (Decker and Ostrander 2014; Johng et al.,
2019). MEIS proteins have been shown to be involved in
the progression of PC by modulating the c-MYC signaling
pathway, cellular proliferation, and were associated with
the invasiveness of PC (Bhanvadia et al., 2018). Depletion
of Meis1 and Meis2 in vivo may cause tumor growth and
an increase in the expression of protumorigenic genes
c-Myc and CD142 (Bhanvadia et al., 2018). Thus, the
expression of Meis1 and Meis2 is related to the inhibition
of metastasis in PC (Bhanvadia et al., 2018). Moreover,
a MEIS cofactor, PBX3, is considered as an important
biomarker in aggressive PC (Ramberg et al., 2016).
The androgen and AR have important functions
during the development and maintenance of PC (Cui
et al., 2014). The potential link between MEIS1 and AR
has been investigated in PC cell lines. In the presence of
synthetic androgen, MEIS1 prevents the transcriptional
function of AR by controlling the translocation of AR
from the cytoplasm to the nucleus. MEIS1 also inhibits AR
binding to the prostate-specific antigen gene promoter and
enhancer regions (Cui et al., 2014). In addition, MEIS1

suppresses the proliferation and anchor-independent
growth of PC cells (Cui et al., 2014). The hypermethylation
and transcriptional downregulation of Meis2 was shown
by DNA methylation and RNA expression analyses of PC
tissue samples (Norgaard et al., 2019).
Castration-resistant PC (CRPC) has a poor prognosis
with a challenging treatment (Jeong et al., 2017).
Progression of androgen-sensitive PC to CRPC occurs via
activation of an inflammatory signaling pathway consisting
of IκBα/NF-κB(p65), MEIS2, miR-196b-3p, and PPP3CC
(calcineurin catalytic subunit γ isoform) (Jeong et al.,
2017). MEIS2 regulates PPP3CC-directed suppression of
IκBα/p65/miR-196b-3p pathway, and therefore inhibits
the development of CRPC (Jeong et al., 2017). Gene array
analyses of seminal vesicle epithelial cells and normal
human prostate epithelium cultures (PrEC) reported
that 15 Hox genes (Hoxa13, Hoxb2-3, Hoxb5-9, Hoxb13,
Hoxc6, Hoxd1, Hoxd3-4, and Hoxd10-11), and their
cofactors Meis1 and Meis2, were differentially expressed
in PrECs (Chen et al., 2012). During embryogenesis,
TWIST1 and HOXA9 function together for organogenesis
of the prostate and they are overexpressed in PC cells
(Malek et al., 2017). The overexpression of Twist1 leads to
migration, invasion, resistance to anoikis, and metastasis
in PC cells. Hoxa9 expression is regulated by TWIST1
(Malek et al., 2017). Additionally, the inhibition of Hoxa9
is enough to abolish TWIST1-promoted metastasis in PC
(Gajula et al., 2013). Moreover, while Meis1, Meis2, and
Pbx1 expressions are downregulated, Hoxa9 expression is
upregulated during the tumor initiation and progression
of PC (Chen et al., 2012). Therefore, these factors could be
useful for both diagnostic and therapeutic purposes of PC
(Chen et al., 2012).
Benign prostate tissue expresses PBX1 and PBX3 in the
nucleus of the basal cells (Ramberg et al., 2016). On the
other hand, immunohistochemical staining has revealed
that cells are PBX3-positive and PBX1-negative in malign
prostate tissue (Ramberg et al., 2016). Moreover, PBX3
localization shifts from the nucleus to the cytosol in malign
tissue (Ramberg et al., 2016). Furthermore, multiple PBX3
isoforms have been reported in PC (Ramberg et al., 2016).
Interestingly, patients who present with moderate PBX3
staining in their PC cells develop CRPC earlier than
patients with strong staining (Ramberg et al., 2016). Pbx1
is downregulated in an androgen-independent PC cell
line that overexpresses the Plzf, which is an androgenresponsive gene (Kikugawa et al., 2006). Moreover, Pbx1
and Hoxc8 expression cause androgen-independent
growth in PC cell lines (Kikugawa et al., 2006). Interestingly,
Pbx1 overexpression has also been shown in PC (Liu et al.,
2019). Additionally, PBX1 leads to both cell proliferation
and chemoresistance in PC (Liu et al., 2019). Moreover, the
stability of PBX1 is controlled by a deubiquitinase USP9x,
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which decreases the polyubiquitination level of PBX1
(Liu et al., 2019). Furthermore, targeting USP9x in Pbx1expressing PC cells leads to apoptosis (Liu et al., 2019). In
PC cells, the expression level of Pbx3 is upregulated. This
is achieved posttranscriptionally by Let-7d, which is an
androgen-regulated microRNA that is downregulated in
PC (Ramberg et al., 2011).
In PC, the high expression of Meis1 and Meis2 is
required for the growth of the tumor (Bhanvadia et al.,
2018). In addition, the expression of Meis1/2 is associated
with antimetastasis in PC (Bhanvadia et al., 2018). Thus,
Meis1/2 expression determines the aggressiveness of PC.
Pbx1–3 and Hoxa9, on the other hand, may function as
oncogenes in PC progression.
2.13. Sarcoma
Mesenchymal cells that are able to differentiate various
tissues, including adipose, muscle, fibrous, cartilage, and
bone, could give rise to sarcoma (Dancsok et al., 2017).
Therefore, sarcoma is really a complex disease and thus
far, more than 70 types of sarcoma have been described
(Dancsok et al., 2017). Sarcoma is genetically complicated
as well, such that an increase in mutational burden, complex
karyotype, translocation, and amplification could be the
genetic basis of the disease (Dancsok et al., 2017). Ewing
sarcoma is one of the most prevalent and overwhelming
primary bone cancers that has been seen both in children
and adolescents (Lin et al., 2019). It has been shown
that MEIS1 is an important factor for cell proliferation
in Ewing sarcoma cells (Lin et al., 2019). In addition, in
vivo silencing of Meis1 remarkably suppresses xenograft
tumor growth (Lin et al., 2019). Moreover, it was reported
that MEIS1 functions together with EWS-FLI1 in Ewing
sarcoma (Lin et al., 2019). G-protein coupled receptor
64 (GPR64) expression is increased in Ewing sarcoma
(Richter et al., 2013). Moreover, the downregulation of
Gpr64 leads to the downregulation of tumor growth and
metastasis, as well as the upregulation of Pbx2, Slit2, and
Mbd2 (Richter et al., 2013).
Meis1-Ncoa2 fusion transcript has been reported in
2 cases with primary renal sarcoma (Argani et al., 2018).
The vascular invasion, cellular necrosis, and perinephric
fat invasion seen in both cases indicated that the Meis1Ncoa2 fusion gene could be malignant (Argani et al.,
2018). The aggressive soft tissue sarcoma of malignant
peripheral nerve sheath tumors (MPNSTs) can occur
both sporadically and together with neurofibromatosis
type 1 (Patel et al., 2016). RNAi screening in MPNST cells
revealed that Meis1 is an important factor (functioning as
a potent oncogene) for MPNST tumor development (Patel
et al., 2016). It was reported that proliferation and cell
survival of MPNSTs by MEIS1 occur via P27Kip inhibition
(Patel et al., 2016). The expression of miR-873 is decreased
in osteosarcoma (OS) tissues and cell lines (Liu et al., 2019).
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The downregulation of miR-873 is related with tumor size,
clinical stage, and distant metastasis (Liu et al., 2019). On
the other hand, Hoxa9 expression is upregulated in OS
tissues, and the silencing of Hoxa9 recovers the miR-873
downregulation effects. This indicates that Hoxa9 is the
target of miR-873 in OS (Liu et al., 2019).
Taken together, Meis1 and Hoxa9 may function as an
oncogene in sarcoma (Lin et al., 2019). The silencing of
Meis1 in the xenograft model was found to suppress tumor
size in sarcoma (Lin et al., 2019). Tumor suppressor roles
of PBX2 have also been demonstrated in sarcoma (Richter
et al., 2013).
2.14. Thyroid cancer
Vriens et al. (2011) showed that Meis2 expression in thyroid
cancer patients older than 40 was about 2.5 times more
frequent (Vriens et al., 2011). Moreover, gene ontology
analysis of 100 genes in 4 classes of thyroid carcinoma,
including papillary thyroid carcinomas, oncocytic variants
of follicular thyroid tumors, tumors of uncertain malignant
potential, and follicular adenomas, revealed that Hoxa9 is
1 of the 7 genes that is differentially expressed in thyroid
carcinomas and is responsible for tumor development
(Jacques et al., 2013).
A comparison of gene expression in MSA, K-119,
KOA-2, 8305C, TCO1 anaplastic thyroid cancer cell lines,
and normal thyroid tissue revealed that the expression of
Hox genes maybe a predictive marker in thyroid cancer
(Takahashi et al., 2004). While Hoxd9 is expressed only
in normal healthy tissue, Hoxb4 is expressed in anaplastic
thyroid cancer cells (Takahashi et al., 2004). Hoxb1,
Hoxd10, Hoxc12, and Hoxd13 were not detected in normal
thyroid tissue or anaplastic thyroid cancer (Takahashi et al.,
2004). In a different study, Hoxa13, Hoxb13, Hoxc13, and
Hoxd13 genes were shown to have abnormal expression in
adenoma, papillary, and follicular thyroid cancer tissues,
and this was confirmed at the protein level (Cantile et al.,
2013). Hoxc10 triggers metastasis and invasion in thyroid
cancer and the expression of Hoxc10 is inversely related to
patient survival time (Feng et al., 2015).
In addition, HOTAIR transcribed from Hox locus has
a significant effect on various thyroid cancers (Wang et al.,
2019a). HOTAIR is upregulated about 80 times in thyroid
cancer (Wang et al., 2019a) and promotes metastasis
of thyroid carcinoma cells (Zhang et al., 2017). When
HOTAIR is downregulated, cell proliferation is inhibited
(Zhang et al., 2017).
Although it still requires further confirmation, Meis2
and Hoxa9 appear to have oncogenic features in thyroid
tumorigenesis. In addition, various Hox isoforms and
HOTAIR also have high expression in thyroid cancer cells
and tissues. However, there is no generalization for all Hox
isoforms. Some Hox isoforms also have tumor-suppressing
properties.
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2.15. Thymoma
Thymoma is among the most frequently seen subtype of
thymic tumors (Comacchio et al., 2019). It is a tumor of
mediastinum that originates from the thymic epithelium
(Comacchio et al., 2019). It can occur at any age with the
same incidence in both men and women (Comacchio et
al., 2019). The upregulation of Meis1 has been observed in
mice thymic epithelial cells (TECs) after the induction of
thymic atrophy by dexamethasone (Popa et al., 2007). In
addition, it was also shown that Meis1 is essential for the
postnatal thymic microenvironment in TECs (Hirayama
et al., 2014). Moreover, an in silico gene expression
analysis of medullary TECs showed that Meis1 and Hoxa7
are upregulated (Rattay et al., 2016). It was reported that
PBX2 has important functions in T-cell development at
both the postnatal and embryonic stages of mice (Penkov
et al., 2005).
Publications about thymoma and the analysis of Meis13, Pbx1-3, or Hoxa9 expression in thymoma are limited. Jia

et al. (2018) showed that expressions of Meis1-3, Pbx1-3,
and Hoxa9 genes were higher than those in normal tissue.
In addition, previously published gene array data (Jia et
al., 2018) were analyzed and differentially expressed genes
were determined in various cancers, including thymoma,
in comparison with healthy tissue (Figure 1). This analysis
revealed that Meis1-3, Pbx1-3, and Hoxa9 genes are highly
upregulated in thymoma when compared to healthy adult
tissues. Further studies involving thymoma cell lines, ex
vivo tumor samples, and in vivo mouse models are still
necessary to determine the relationship of these genes with
the development of thymoma.
2.16. Comparison of MEIS expression in various cancer
types and their corresponding health tissues
The role of MEIS proteins have been largely studied
in embryonic development and cancer progression;
however, their function in adult tissues have still not
been fully established (Toresson et al., 2000; Choe et

Figure 1. Expression profile of Meis1-3, Pbx1-3, and a commonly associated Hoxa9 gene in cancer tissues when compared to adult healthy
tissue. Cancer types could be separated into 3 groups based on the overall expression of Meis and its associated factors: upregulated,
inconclusive, and downregulated groups of cancers. Note that these are the average of all of the subtypes in the indicated cancers.
ACC: adrenocortical carcinoma, BLCA: bladder urothelial carcinoma, BRCA: breast invasive carcinoma, CESC: cervical squamous
cell carcinoma and endocervical adenocarcinoma COAD: colon adenocarcinoma, DLBC: lymphoid neoplasm diffuse large B-cell
lymphoma, ESCA: esophageal carcinoma, GBM: glioblastoma multiforme, HNSC: head and neck squamous cell carcinoma, KICH:
kidney chromophobe, KIRC: kidney renal clear cell carcinoma, KIRP: kidney renal papillary cell carcinoma, LAML: acute myeloid
leukemia, LGG: brain lower grade glioma, LIHC: liver hepatocellular carcinoma, LUAD: lung adenocarcinoma, LUSC: lung squamous
cell carcinoma, OV: ovarian serous cystadenocarcinoma, PAAD: pancreatic adenocarcinoma, PRAD: prostate adenocarcinoma, READ:
rectum adenocarcinoma, SKCM: skin cutaneous melanoma, STAD: stomach adenocarcinoma, TGCT: testicular germ cell tumors,
THCA: thyroid carcinoma, THYM: thymoma, UCEC: uterine corpus endometrial carcinoma, UCS: uterine carcinosarcoma.

339

GİRGİN et al. / Turk J Biol
al., 2002; Zhang et al., 2002; Zhang et al., 2006). Several
adult tissues demonstrate high levels of Meis expression
(Uhlen et al., 2015). Meis1, Meis2, and Meis3 are highly
expressed in female reproductive tissues (Uhlen et al.,
2015; Wu et al., 2016). MEIS1 organizes sex steroid
hormones and reproduction with HOXA10 and PBX2
interactions (Sarno et al., 2005; Hu et al., 2014). Adrenal
glands have a high expression of Meis1, followed by the
adrenal cortex, colon, appendix, and ovaries (Wu et al.,
2016). Unlike Meis1, the expression of Meis2 is elevated
in the brain, pancreas, and prostate (Wu et al., 2016).
MEIS2, which regulates neurogenesis with cofactors such
as PAX6, FOXP1, FOXP2, FOXP3, and PBX3, provides
dopaminergic periglomerular fate specification (Co et al.,
2020; Agoston et al., 2014; Grebbin et al., 2016). MEIS3,
which is overexpressed in the brain, interacts together
with PBX4, HOXB1B, and manages the hindbrain fate
utilization of the FGF/MAPK and planar cell polarity
signaling pathway (Aamar and Frank, 2004). MEIS3 in
the hindbrain has a regulatory role that induces neural
progenitor cells and maintains the neural stem cell pool
(Vlachakis et al., 2001; Waskiewicz et al., 2001).
According to the GEPIA and BioGPS datasets, the
expression of Meis1, Meis2, and Meis3 vary in different
cancers (Wu et al., 2013; Wu et al., 2016; Tang et al., 2017).
Interestingly, Meis1 is overexpressed in lymphoid neoplasm
diffuse large B-cell lymphoma, cholangiocarcinoma,
kidney renal clear cell carcinoma, ovarian serous
cystadenocarcinoma, glioblastoma multiforme, acute
myeloid leukemia, brain lower grade glioma, and thymoma
(Wu et al., 2013; Wu et al., 2016; Tang et al., 2017). The
Meis2 expression pattern in cancer tissues differs from that
of Meis1, and it also differs in adult tissues. Meis2 has a high
expression profile in cholangiocarcinoma, glioblastoma,
brain lower grade glioma, pancreatic adenocarcinoma,
liver hepatocellular carcinoma, skin cutaneous melanoma,
stomach adenocarcinoma, and thymoma. MEIS3, which is
the least studied isoform of the MEIS proteins, is highly
expressed in breast-invasive carcinoma, diffuse large B-cell
lymphoma, kidney renal papillary cell carcinoma, head,
and neck SCC, and pancreatic adenocarcinoma, unlike
other isoforms (Wu et al., 2013; Wu et al., 2016; Tang et
al., 2017). It is not possible to identify a cancer in which
all of the MEIS isoforms are expressed at a high level. As
in normal tissues, the expressions of MEIS in cancers are
quite different from each other. Only in lower-grade brain
glioma are the expressions of all MEIS isoforms higher
when compared to healthy tissue (Wu et al., 2013; Wu et
al., 2016; Tang et al., 2017).
A study by Jia et al. (2018) demonstrated the profiling of
TALE and HOX protein members in cancers and revealed
a complex network of MEIS isoforms in cancer biology.
The expression of MEIS isoforms varied in almost all
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cancer tissues when 28 different cancer types were studied.
Meis1, Meis2, and Meis3 were upregulated in lymphoid
neoplasm diffuse large B-cell lymphoma and thymoma
cancers. Meis1 was upregulated in acute myeloid leukemia
and glioblastoma. In other cancers, the expression of
Meis1 was either reduced or did not lead to a significant
change. Meis2 and Meis3 expression were increased in
pancreatic adenocarcinoma. Meis3, unlike other isoforms,
was increased in head and neck SCC (Jia et al., 2018).
Overall, the expression of Meis1–3, Pbx1–3, and their
associated partner, Hoxa9, were observed as upregulated
in thymoma, pancreatic adenocarcinoma, glioblastoma,
glioma, lymphoma, and leukemia when compared
to corresponding healthy adult tissues (Figure 1). In
particular, Meis1 was upregulated in breast, neuroblastoma,
gynecologic, skin, sarcoma, and thymoma cancers, which
may be associated with cancer cell survival, proliferation,
and tumorigenesis. Meis1 and Meis2 were upregulated
in parallel, only in neuroblastoma, gynecologic, and
thymoma cancers. MEIS2 has been shown to induce
metastasis in bladder cancer (Xie et al., 2019). On the
other hand, MEIS1 has a tumor suppressor role in some
cancers. MEIS1 has a cancer growth suppressor role in
kidney and PC (Chen et al., 2012; Zhu et al., 2017). MEIS2
may also function as a tumor suppressor in PC (Chen et
al., 2012). In PC, there is no tumor aggression in patients
with high Meis1 and Meis2 expression (Bhanvadia et al.,
2018). MEIS1 could trigger cell proliferation in colorectal
cancer, while MEIS2 determines the relationship between
colorectal cancer growth and death (Wan et al., 2019).
MEIS2 could increase colorectal dependent cell death
(Wang et al., 2019b). In glioma, Meis1 expression is high,
while Meis2 expression is low. Unfortunately, studies
on the role of Meis3 in cancer biology are very limited.
Given the importance of MEIS isoforms and cofactors
in cancer biology, it is clear that the effects of MEIS3 on
cancer biology need to be investigated. In fact, the same
MEIS isoform, along with associated cofactors, may have 2
different functions, as a tumor suppressor or an oncogene,
in different cancers. This requires further analysis and
understanding of the complex interaction of MEIS proteins
in different cofactors to form a conclusion about the final
outcome of MEIS activity in cancer, as well as adult tissues.
3. Noncoding RNA-based therapies in cancer and
modulation of MEIS and its partner expression
Noncoding RNAs are involved in various biological
processes, including the regulation of translation, RNA
splicing, DNA regulation, gene regulation, genome
defense, and chromosome structure, and may act as a
hormone (Sanchez Calle et al., 2018). The expression of
noncoding RNAs has often been found to impair cancer
(Di Leva et al., 2014; Hayes et al., 2014; Sanchez Calle et al.,
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2018). Noncoding RNAs, especially siRNAs and lncRNAs,
have the potential to be used as chemotherapeutic agents
in cancer treatments (Drosopoulos and Linardopoulos,
2019). siRNA, which is a double-stranded RNA molecule
with a length of 20–25 base pairs, is complementary
to the mRNA of the specific gene (Yarian et al., 2019).
Therefore, the expression level of an oncogene can be
targeted by limiting the translation level with siRNA
treatments (Drosopoulos and Linardopoulos, 2019; Yarian
et al., 2019). Several siRNAs have been shown to reduce
cancer proliferation, metastasis, invasion, and impaired
cell cycle (Yarian et al., 2019). In addition, some siRNAs
could stimulate apoptosis in PC, OSCC, lung cancer,
nasopharyngeal carcinoma, osteosarcoma, and others
(Feng et al., 2017; Liu et al., 2017; Shi et al., 2018; Wang et
al., 2018c; Wang et al., 2018d; Wang et al., 2018e; Wang et
al., 2019c)
miRNAs could act as tumor suppressors or oncogenes
(Calin et al., 2002; Peng and Croce, 2016). For instance,
miR-888 promotes the spread of cancer to the body via
metastasis and invasion (Li et al., 2019b). miR-31, miR-34,
miR-182, miR-211, and miR-599 expression are positively
correlated with Satb2 in carcinogenesis (Chen et al., 2019).
miR-206 reduces Pax3 and Met gene expression and leads
to the reduction of malignancy of osteosarcoma (Zhan
et al., 2019). On the other hand, miR-181c and miR133b have the opposite effect by increasing the sensitivity
of chemotherapies (Han et al., 2019). However, some
studies have shown that miR-133b causes resistance to
chemotherapy (Lin et al., 2018). miR-148a, miR-374b,
and miR-433 decrease cell proliferation and invasion in
pancreas and cervical cancer, and NSCLC, respectively
(Liu et al., 2018; Sun et al., 2019; Xia et al., 2019). The
outlined functions of miRNAs are new evidence to be
targeted for chemotherapy (Sun et al., 2019).
lncRNAs, which are more than 200 nucleotides
in length, act as negative or positive regulators in
differentiation and development processes, and provide
homeostasis (Carninci and Hayashizaki, 2007; St Laurent et
al., 2015; Renganathan and Felley-Bosco, 2017). lncRNAs
are involved in epigenetic regulation, posttranscriptional
regulation could act as either a tumor suppressor or
oncogene in cancer (Bach and Lee, 2018). In addition,
lncRNAs can be used for the purpose of early diagnosis
and prognosis of cancer (Di Leva et al., 2014; Hayes et al.,
2014). lncRNA CASC11, TUG1, PCAT6, LOC730100,
and LINK-A have important functions in the proliferation
and metastasis of the bladder cancer, laryngocarcinoma,
cervical, glioblastoma, and ovarian carcinoma (Li et al.,
2019c; Luo et al., 2019; Lv et al., 2019; Zhang et al., 2019;
Zhuang et al., 2019). Surprisingly, it was also observed that
lncRNA MALAT1 had effects on energy metabolism that

are known to be associated with metastasis in hepatocellular
carcinoma and the upregulation of glycolysis genes
(Malakar et al., 2019). Thus, the relationship of lncRNAs
involved in the Warburg effect, which is an important
phenomenon in cancer metabolism, have been shown
(Malakar et al., 2019).
When mouse embryonic fibroblast cells were
transfected with shPbx, the levels of MEIS1 and MEIS1PREP1a were also reduced at the protein level (Dardaei
et al., 2014). MLL-AF4 siRNA treatment also led to a
reduction of the expression levels of Hoxa9 and the
Meis1 signaling pathway, which in turn, prevented
engraftment and clonality (Thomas et al., 2005).
Moreover, Hoxa9 specific siRNA transfected THP cells
demonstrated increased apoptosis within 5 days (Faber et
al., 2009). When human EZH2, a member of the family
of polycomb repressive complex, is suppressed by siRNA,
the expression levels of Meis1 and Hoxa9 are reduced in
human acute leukemia cells (Fiskus et al., 2006). In the
PC cells (i.e. Panc1), mitochondrial activity is decreased
by the suppression of TALE protein family members by
siRNA (Tomoeda et al., 2011). Targeting of Meis and its
partners by siRNA suggests an awaiting potential for an
in vitro chemotherapeutic approach by modulating related
mitochondrial and metabolic pathways.
4. Targeting MEIS, its associated partners and pathways
in cancer
Small molecules alter the activity or function of target
macromolecules by binding to them (Arkin and Wells,
2004). Small molecules could inhibit protein-protein/
DNA-protein interactions; therefore, the utilization of
small molecules allows an understanding of the biological
processes and could be used in the treatment of various
diseases (Arkin et al., 2014). Small molecules that are
effective in cellular signaling pathways are easily diffused
intracellularly, and thus can be transported very rapidly
inside of the intercellular region (Yang and Hinner,
2015). Except for protein-based drugs, the majority of
pharmaceutically active compounds are small molecules
(Lu et al., 2011).
Over recent decades, small molecules have been
intensely studied for their utilization in cancer therapy.
MEIS1 has been shown to transactivate HIF-1α and HIF2α expression, modulate cellular metabolism, and redox
state (Simsek et al., 2010; Kocabas et al., 2012; Mahmoud
et al., 2013; Aksoz et al., 2018). There is a direct correlation
between HIF-1α and mitochondria activity in healthy
cells. HIF-1α and HIF-2α protect the cell against ROSdependent apoptosis. Some of the small molecules that
disrupt mitochondria activity via inhibiting HIFs lead to
cancer cell apoptosis (Polson et al., 2018; Wei et al., 2018;
Marciano et al., 2019).
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MEIS, associated HOX proteins, and downstream
pathways may be prominent chemotherapy targets for
cancer treatment. To this end, various studies over the
last decade have targeted the TALE family of proteins and
their interaction with MEIS proteins with small molecules
or peptides in cancer. A peptide, for instance, designed
to disrupt the HOX/PBX/DNA interaction reduced the
proliferation of T3M4 PC cells, K562 leukemia cells,
and MJT1 melanoma cells (Aulisa et al., 2009). Two
small peptides, HXR9 and CXR9, were shown to induce
apoptosis in NSCLC cells, breast, ovarian, prostate, and
meningioma cells by disrupting the interaction of HOX and
PBX (Plowright et al., 2009; Morgan et al., 2010; Morgan
et al., 2012; Ando et al., 2014). In neuroblastoma, stable
PBX1-MEIS1 interaction provides an overexpression of
Phox2b (Di Zanni et al., 2015). PHOX2B expression was
reported as reduced in neuroblastoma cells as a result of
small molecule combination, which included curcumin,
SAHA, and trichostatin (Di Zanni et al., 2015).
Several MLL cell lines have overexpressed Meis1
and Bcl2 (Somers et al., 2016). As a result of smallmolecule library screening, it was observed that smallmolecule CCI-007, although not specific for MEIS1,
had a cytotoxic effect within few hours in CALM-AF10,
MLL-r, and SET-NUP214 leukemia cell lines (Somers
et al., 2016). Small-molecule CCI-007 triggers caspasedependent apoptosis due to mitochondria depolarization
and alters the expression of MLL-related genes (Somers
et al., 2016). MLL cell lines have different metabolic
phenotypes and mitochondrial respiration through
different molecular pathways (Somers et al., 2019). CCI006 also impairs mitochondria in the case of CCI-007 and
increases apoptosis. Intriguingly, small-molecule CCI-006
demonstrates a cytotoxic effect in MLL, specifically in a low
Meis expressing subset of cells. This suggests that MEIS+
cells may not be affected by CCI-007-induced apoptosis.
5. Novel small-molecule MEIS inhibitors
Studies over the last decade have shown that MEIS and its
partner proteins have crucial roles in regeneration, stem
cell/progenitor function, cellular metabolism, RLS, and
tumorigenesis (Wang et al., 2018a; Sarayloo et al., 2019;
Paul et al., 2020). Various cancers overexpress MEIS
proteins and their cofactors. MEIS proteins have been
found to interact with PBX1 and HOXA9 while driving
tumorigenesis (Collins and Hess, 2016). Small-molecule
inhibitors blocking PBX1-DNA interaction have been
recently described (Wang et al., 2018f). These inhibitors
disrupt DNA-protein interaction instead of proteinprotein interaction; therefore, they are more efficient than
previously developed inhibitors in terms of in vitro usage,
cellular penetration, and/or solubility (Wang et al., 2018f).
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Recently, our proprietary tools and expertise were used
in MEIS biology to develop MEIS inhibitors (Kocabas,
2019; Turan et al., 2020). Also performed were in silico, in
vitro, ex vivo, and in vivo assays to validate small-molecule
MEIS inhibitors. As a result, 2 newly identified smallmolecule MEIS inhibitors (namely MEISi-1 and MEISi-2)
are cell-permeable and dose-dependent, and specifically
inhibit MEIS HD-DNA interaction; thereby preventing the
transactivation of MEIS-targeted gene expression (Figure
2). They have a high affinity and preferential binding
to MEIS HD in comparison to other TALE families of
HD proteins. They inhibit MEIS-Luc activity in a dosedependent manner as low as 100 nM. Meis1 is known to
transcriptionally regulate the expression of HIF-1α, HIF2α, and p21 (Kocabas et al., 2012; Muralidhar and Sadek,
2016). MEIS inhibitors downregulate the expression of
Meis1, Meis2, and MEIS target genes, including HIF1α, HIF-2α, and p21. They demonstrate a tissue and
cell type-specific phenotype, and MEISi-1 and MEISi-2
could induce human and mouse hematopoietic stem cell
expansion, self-renewal, and increased CFU-GEMM. The
expression of Meis1 and HIF-2α is downregulated by them
in bone marrow. They induce mouse hematopoietic stem
cell expansion in vivo.
Studies conducted over past decades have suggested
that MEIS and MEIS partners are crucial for cancer biology.

Figure 2. Newly developed small-molecule MEIS inhibitors
target HD-DNA interaction. Crystal structure of MEIS and
HOXB13 homeodomains bound to DNA are shown.
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The development of small molecules targeting MEIS or its
cofactors in drug development can be a valuable asset in
the chemotherapy of MEIS-positive cancers.
6. Conclusion
Since their discovery in 1995, MEIS proteins have
been reported to have diverse roles in development,
metabolism, homeostasis, regeneration, and cancer
biology. MEIS isoforms (MEIS1, MEIS2, and MEIS3)
accomplish developmental and physiological processes in
collaboration with HOX and PBX proteins. MEIS proteins
are able to alter the cell cycle and energy metabolism of
hematopoietic stem cells by transactivating HIFs. It has
been reported that cells undergo apoptosis as a result
of impaired MEIS expression. Disruption of the MEISPBX interaction could also cause caspase-dependent
apoptosis in a cell-dependent manner. Expressions of
MEIS and associated proteins are tightly regulated during
development and in adult tissues that contribute to overall
homeostasis in the organism.
In cancer biology, Meis genes were first described as an
oncogene in the leukemia mouse model. Over the last few

decades, many studies have been conducted to understand
the role of MEIS proteins in leukemia when compared to
other cancer types. Over recent years, the use of clinical
data has demonstrated that MEIS and varying MEIS
partners play crucial roles in the development of various
cancers, especially in neuroblastoma and cancers of the
male and female reproductive system (Spieker et al., 2001;
Uhlen et al., 2015) (summarized in Table 2). Although Meis
was first described as an oncogene, a number of studies
have demonstrated the tumor suppressor role as well
(Song et al., 2017; Zhu et al., 2017). MEIS proteins could,
for instance, suppress proliferation, migration, invasion,
and metastasis of renal cell carcinoma and gastric cancers
(Song et al., 2017; Zhu et al., 2017).
Knowledge about MEIS and MEIS partner proteins is
increasing gradually. The relationship of MEIS and MEIS
partner proteins with various cancer types was discussed
herein, as well as the treatment strategies of these cancers
with small molecules or noncoding RNAs (Figure 3).
While the expressions of MEIS or its partner proteins in
several cancer types are increased, they are decreased in
many others. Conventional chemotherapy is often painful

Table 2. Role of MEIS proteins or their cofactors in various solid cancers.
Cancer type
Bladder
Breast
Colorectal

Involvement of the MEIS proteins or their cofactors in tumorigenesis
MEIS2 could promote metastasis. Hoxa13 and Hoxb13 are
overexpressed.
Meis1 is upregulated in breast cancer
Meis2 expression is associated with mortality in colorectal cancer.
Overexpression of Meis1 diminishes cell proliferation.

Glioblastoma

Overexpression of Pbx3, Hoxa10-13, and Hoxc6-10 causes cell
proliferation and chemotherapy resistance

Glioma

Meis1 is overexpressed in glioma.

Neuroblastoma Overexpression of Meis1 and Meis2 could induce tumor progression.

Reference
Xie et al. (2019)
Doolan et al. (2009)
Crist et al. (2011), Wang et al. (2019)
Geerts et al. (2003), Jones et al. (2000),
Kim et al. (2014), Manohar et al. (1993),
Spieker et al. (2001)
Berdasco et al. (2009), Vastrad et al.
(2017)
Spieker et al. (2001), Zha et al. (2014)

Kidney

Overexpression of Meis1 inhibits renal cell carcinoma cell proliferation. Zhu et al. (2017)

Lung

Endogenous Meis1 expression could inhibit cell proliferation

Li et al. (2014)

Skin

MEIS1 promotes tumor development. PBX2 and HOXB7 determines
aggressiveness in melanoma.

Errico et al. (2013), Okumura et al.
(2014)

Oral

Hoxa9 is upregulated in oral cancer.

Gynecologic

Meis1-2 and Pbx1-3 are upregulated in gynecologic cancers

Carrera et al. (2015)
Li et al. (2017), Li et al. (2019), Zhu et al.
(2012)

Thyroid

Meis1 and Pbx3 give metastatic capabilities to pancreatic tumors. PBX1
is involved in tumor progression.
Meis1 and Meis2 expression determine the aggressiveness of prostate
cancer.
Silencing of Meis1 in a xenograft model was found to suppress tumor
size
Meis2 and Hoxa9 is upregulated in thyroid cancer.

Thymoma

Meis1-3, Pbx1-3, and Hoxa9 are upregulated in thymoma.

Pancreatic
Prostate
Sarcoma

Qiu et al. (2019), Scarlett et al. (2011)
Bhanvadia et al. (2018)
Lin et al. (2019), Patel et al. (2016)
Jacques et al. (2013), Vriens et al. (2011)
Jia et al. (2018)
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for cancer patients and, unfortunately, the success rate is
limited. Therefore, researchers aim to develop targeted
chemotherapy approaches. In a number of in vitro studies
where MEIS and MEIS partner proteins were targeted
indirectly by small molecules or noncoding RNAs,
cancer proliferation, spread, metastasis, and invasion
could have been suppressed. In conclusion, MEIS and its
partner proteins are key cancer biomarkers and could be
therapeutically targeted in cancer treatments.
6.1. Highlights
• MEIS proteins in cooperation with PBX and HOX
proteins modulate tumorigenesis and development.
• Meis1–3, Pbx1–3, and Hoxa9 are upregulated in
thymoma, pancreatic adenocarcinoma, glioma,
glioblastoma, and leukemia/lymphoma when
compared to healthy tissue.

•
•

Meis1–3, Pbx1–3, and Hoxa9 are downregulated in
lung, skin, and prostate cancers.
Every cancer type includes at least a subtype of cancer
with MEIS+/high expressivity.
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Figure 3. Potent therapeutic approaches for MEIS+/High cancers. Meis1-3 and its cofactors are prominent oncogenic transcription factors.
Various cancers could occur due to misregulation or mutations the MEIS transcription factors, which can be classified as Meis+/High and
Meis–/Low. There are 2 types of potent targeted approaches for Meis+/High cancers: RNA-based methods and inhibitors/disrupters. While
RNA-based methods inhibit the translation of Meis1-3 transcripts, the disruptors bind the MEIS protein in order to block its function or
interaction with other cofactors. Thus, these approaches may cause the inhibition of tumor growth, induction of cancer cell apoptosis,
and modulation of metabolic preference.
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